27 research outputs found
PAROXETINE AND FLUOXETINE EFFECTS ON MOOD AND COGNITIVE FUNCTION IN DEPRESSED NONDEMENTED ELDERLY PATIENTS. G.B
No full textEffetto della composizione aminoacididca della dieta sulla produzione quanti-qualitativa di latte negli ovini
No full textDICOM-MIABIS integration model for biobanks: a use case of the EU PRIMAGE project
No full textPRIMAGE is a European Commission-financed project dealing with medical imaging and artificial intelligence aiming to create an imaging biobank in oncology. The project includes a task dedicated to the interoperability between imaging and standard biobanks. We aim at linking Digital imaging and Communications in Medicine (DICOM) metadata to the Minimum Information About BIobank data Sharing (MIABIS) standard of biobanking. A very first integration model based on the fusion of the two existing standards, MIABIS and DICOM, has been developed. The fundamental method was that of expanding the MIABIS core to the imaging field, adding DICOM metadata derived from CT scans of 18 paediatric patients with neuroblastoma. The model was developed with the relational database management system Structured Query Language. The integration data model has been built as an Entity Relationship Diagram, commonly used to organise data within databases. Five additional entities have been linked to the “Image Collection” subcategory in order to include the imaging metadata more specific to the particular type of data: Body Part Examined, Modality Information, Dataset Type, Image Analysis, and Registration Parameters. The model is a starting point for the expansion of MIABIS with further DICOM metadata, enabling the inclusion of imaging data in biorepositories
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study
No full textIron chelation is controversial in higher risk myelodysplastic syndromes (HR-MDS), outside the allogeneic transplant setting. We conducted a retrospective, multicentre study in 51 patients with transfusion-dependent, intermediate-to-very high risk MDS, according to the revised international prognostic scoring system, treated with the oral iron chelating agent deferasirox (DFX). Thirty-six patients (71%) received azacitidine concomitantly. DFX was given at a median dose of 1000 mg/day (range 375-2500 mg) for a median of 11 months (range 0.4-75). Eight patients (16%) showed grade 2-3 toxicities (renal or gastrointestinal), 4 of whom (8%) required drug interruption. Median ferritin levels decreased from 1709 mu g/l at baseline to 1100 mu g/l after 12 months of treatment (P = 0.02). Seventeen patients showed abnormal transaminase levels at baseline, which improved or normalized under DFX treatment in eight cases. One patient showed a remarkable haematological improvement. At a median follow up of 35.3 months, median overall survival was 37.5 months. The results of this first survey of DFX in HR-MDS are comparable, in terms of safety and efficacy, with those observed in lower-risk MDS. Though larger, prospective studies are required to demonstrate real clinical benefits, our data suggest that DFX is feasible and might be considered in a selected cohort of HR-MDS patients
Recommended from our members
Class of 1960 - Day Section
No full textAbramson, I. Addess, A. Bardavid, R. Berger, S. Berman, P. Bernstein, S. Betsos, P. Blatt, D. Blittner, A. Brecher, G. Budin, J. Cahn, R. Callo, D. Cohen, M. Cohn, L. Colantuono, J. Creditor, P. Delman, N. Demartino, N. Dounias, P. Drossman, L. Duban, M. Edelman, H. Fleischer, B. Fleischer, E. Floyd, M. Fox, S. Frey, S. Friedman, H. Friedman, R. Frommer, W. Glaser, J. Gargano, H. Goldberg, B. Goldberg, G. Goldstein, Melvin. Goldstein, Michael. Goldstein, Mitchell. Goldstein, S. Goldstein, W. Gordon, S. Greenberg, S. Greene, A. Heller, A. Judlowitz, D. Katz, E. Koch, A. Koval, M. Lashin, M. Lazarowitz, H. Lebowitz, A. Leff, R. Leibowitz, G. Levenson, S. Levy, R. Lieberstein, S. Lipnack, M. Lobel, S. Mammana, S. Maroshick, E. Mendelson, A. Merani, P. Miller, C. Milonas, L. Morris, M. Moussouttas, D. Nitsberg, M. Ochs, M. O\u27Donnell, J. Perelman, M. Price, E. Ralph, W. Reich, E. Reiver, K. Ripton, J. Rolnick, G. Romanoff, G. Rosen, R. Ross, R. Roth, P. Rubin, M. Samuels, A. Scapicchio, F. Schachter, M. Schaumberger, N. Schmeltzer, D. Schneider, R. Seif, A. Shapiro, L. Silverman, B. Silverman, M. Simon, G. Simon, L. Sipress, M. Spiegelman, J. Strassberg, M. Thomas, C. Tremsky, W. Trolman, D. Walker, E. Weisman, M. Weiss, H. Weiswasser, R. Wessler, R. Wexler, E. Wildermuth, E., Jr. Wolfe, H. Youngstein, M. Zeitlan, B. Ziegler, G. Zimmerman, A. Zipkin, N.https://brooklynworks.brooklaw.edu/bls_classphotos/1070/thumbnail.jp
Class of 1960 - Day Section
No full textAbramson, I. Addess, A. Bardavid, R. Berger, S. Berman, P. Bernstein, S. Betsos, P. Blatt, D. Blittner, A. Brecher, G. Budin, J. Cahn, R. Callo, D. Cohen, M. Cohn, L. Colantuono, J. Creditor, P. Delman, N. Demartino, N. Dounias, P. Drossman, L. Duban, M. Edelman, H. Fleischer, B. Fleischer, E. Floyd, M. Fox, S. Frey, S. Friedman, H. Friedman, R. Frommer, W. Glaser, J. Gargano, H. Goldberg, B. Goldberg, G. Goldstein, Melvin. Goldstein, Michael. Goldstein, Mitchell. Goldstein, S. Goldstein, W. Gordon, S. Greenberg, S. Greene, A. Heller, A. Judlowitz, D. Katz, E. Koch, A. Koval, M. Lashin, M. Lazarowitz, H. Lebowitz, A. Leff, R. Leibowitz, G. Levenson, S. Levy, R. Lieberstein, S. Lipnack, M. Lobel, S. Mammana, S. Maroshick, E. Mendelson, A. Merani, P. Miller, C. Milonas, L. Morris, M. Moussouttas, D. Nitsberg, M. Ochs, M. O\u27Donnell, J. Perelman, M. Price, E. Ralph, W. Reich, E. Reiver, K. Ripton, J. Rolnick, G. Romanoff, G. Rosen, R. Ross, R. Roth, P. Rubin, M. Samuels, A. Scapicchio, F. Schachter, M. Schaumberger, N. Schmeltzer, D. Schneider, R. Seif, A. Shapiro, L. Silverman, B. Silverman, M. Simon, G. Simon, L. Sipress, M. Spiegelman, J. Strassberg, M. Thomas, C. Tremsky, W. Trolman, D. Walker, E. Weisman, M. Weiss, H. Weiswasser, R. Wessler, R. Wexler, E. Wildermuth, E., Jr. Wolfe, H. Youngstein, M. Zeitlan, B. Ziegler, G. Zimmerman, A. Zipkin, N.https://brooklynworks.brooklaw.edu/bls_classphotos/1070/thumbnail.jp
Class of 1960 - Day Section
No full textAbramson, I. Addess, A. Bardavid, R. Berger, S. Berman, P. Bernstein, S. Betsos, P. Blatt, D. Blittner, A. Brecher, G. Budin, J. Cahn, R. Callo, D. Cohen, M. Cohn, L. Colantuono, J. Creditor, P. Delman, N. Demartino, N. Dounias, P. Drossman, L. Duban, M. Edelman, H. Fleischer, B. Fleischer, E. Floyd, M. Fox, S. Frey, S. Friedman, H. Friedman, R. Frommer, W. Glaser, J. Gargano, H. Goldberg, B. Goldberg, G. Goldstein, Melvin. Goldstein, Michael. Goldstein, Mitchell. Goldstein, S. Goldstein, W. Gordon, S. Greenberg, S. Greene, A. Heller, A. Judlowitz, D. Katz, E. Koch, A. Koval, M. Lashin, M. Lazarowitz, H. Lebowitz, A. Leff, R. Leibowitz, G. Levenson, S. Levy, R. Lieberstein, S. Lipnack, M. Lobel, S. Mammana, S. Maroshick, E. Mendelson, A. Merani, P. Miller, C. Milonas, L. Morris, M. Moussouttas, D. Nitsberg, M. Ochs, M. O\u27Donnell, J. Perelman, M. Price, E. Ralph, W. Reich, E. Reiver, K. Ripton, J. Rolnick, G. Romanoff, G. Rosen, R. Ross, R. Roth, P. Rubin, M. Samuels, A. Scapicchio, F. Schachter, M. Schaumberger, N. Schmeltzer, D. Schneider, R. Seif, A. Shapiro, L. Silverman, B. Silverman, M. Simon, G. Simon, L. Sipress, M. Spiegelman, J. Strassberg, M. Thomas, C. Tremsky, W. Trolman, D. Walker, E. Weisman, M. Weiss, H. Weiswasser, R. Wessler, R. Wexler, E. Wildermuth, E., Jr. Wolfe, H. Youngstein, M. Zeitlan, B. Ziegler, G. Zimmerman, A. Zipkin, N.https://brooklynworks.brooklaw.edu/bls_classphotos/1070/thumbnail.jp
Somministrazione mattutina o serale di bromperidolo nel trattamento del paziente schizofrenico
No full textDepressive symptoms, vascular risk factors and mild cognitive impairment. The Italian longitudinal study on aging.
No full textAims: We evaluated the impact of depressive symptoms on
the rate of incident mild cognitive impairment (MCI) after a
3.5-year follow-up, and we assessed the interaction between
depressive symptoms and vascular risk factors for incident
MCI. Methods: A total of 2,963 individuals from a sample of
5,632 65- to 84-year-old subjects were cognitively and functionally evaluated at the 1st and 2nd surveys of the Italian
Longitudinal Study on Aging, a prospective cohort study
with a 3.5-year follow-up. MCI and dementia were classified
using current clinical criteria. Depressive symptoms were
measured with the Geriatric Depression Scale. Results:
Among the 2,963 participants, 139 prevalent MCI cases were diagnosed at the 1st survey. During the 3.5-year follow-up,
105 new events of MCI were diagnosed. We did not observe
any significant association between depressive symptoms
and incident MCI (RR = 1.25, 95% CI = 0.85–1.84, 2 = 1.30,
p ! 0.25). No sociodemographic variables or vascular risk
factors modified the relationship between depressive symptoms and incident MCI. Conclusion: In our population, depressive symptoms were not associated with the rate of incident MCI. Our findings did not support a role of
sociodemographic variables or vascular risk factors in the
link between depressive symptoms and incident MCI
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
No full textTherapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are available about bortezomib re-use at first relapse. This multicenter, observational, retrospective study enrolled 134 MM patients with significant response after bortezomib-based frontline regimens and who had received a first salvage treatment containing bortezomib at relapse. The overall response rate was 71%, including 40% partial responses, 24% very good partial responses, and 7% complete responses. Re-treatment was well-tolerated, with no significant new or unexpected toxicities observed. The median duration of second progression-free survival (PFS) was 15 months, while median PFS2 was 55 months. With a median follow-up of 56 months, overall survival was 94 months for the entire series, without significant differences between patients undergoing or not undergoing transplant procedures. This real-life survey indicates that re-treatment including bortezomib as a first salvage therapy could be still considered in MM patients achieving durable response after initial exposure to bortezomib
